HELLO! i’m Isabel
Dr Isabel Rodríguez Amado is a Research Fellow at INL funded by a Marie-Curie COFUND. She works at the Department of Life Sciences, within the Food Processing research group.
Isabel Rodríguez holds a Degree in Biochemistry (2003) at the Complutense University of Madrid. She completed her PhD in Food Science and Technology at the University of Vigo (2009). As a postdoc, she has gained multidisciplinary national and international research experience. Through these years, her research has covered disciplines from Food Science and Technology, Biotechnology, Valorization and Food Processing, to Biomaterials Science and Drug Delivery at different institutions in Spain, Portugal and the UK. She has been granted with National and International Postdoctoral grants and has a wide network of national and international collaborations.
The main topics of her research are related to Food Biotechnology, including:
(1) Production and encapsulation of bioactive compounds
(2) Recovery and production of high-value-added products from by-products of the marine and agriculture industrial sectors
The results of her research activity yielded so far over 30 papers published in international peer-reviewed journals indexed in the SCI, eight book chapters, and 18 conference contributions. Isabel has co-supervised 1 Master Thesis, 3 Master Project and 8 Projects of undergraduate students. She has teaching experience with over 300 h of lecturing in Food Chemistry and Biochemistry disciplines.
The Cofund project
The COFUND project led by Dr Isabel Rodríguez relays on nanotechnology and microbiology to develop a new treatment for obesity based in the actuation on the microbiota-gut-brain axis. Complex mechanisms linking the gastrointestinal (GI) tract and the brain are still being elucidated, but it is well established that, satiation signals are mediated by gut hormones and peptides produced by enteroendocrine cells from the wall of the GI tract and transported from the blood to the brain. Also, it is well known that the microbiota, commensal microorganisms of the GI tract, play an important role in human physiology and particularly, in the GI health condition of the individuals. Gut disorders, including obesity and colorectal cancer, are associated with dysbiosis or altered intestinal microbiota.
In this context, the goal of her project is developing a safe, long-term effective, anti-obesity treatment with the benefits of bariatric surgery and without its clinical complications, based in the combination of bioactive peptides and a selection of symbiotics modulating the levels of hormones regulating satiety.
In particular, we aim to develop a whole multifunctional smart oral delivery system, including on-demand nanocarriers for gut hormone mediators and probiotic bacteria that will reach the colon and displace harmful bacteria, providing them with a competitive advantage through their encapsulation in prebiotic materials.
Preliminary results of the research group, together with collaborations with Spanish and Brasilian research groups experts in satiation and probiotics, encourage us to give our best to this challenging project that will hopefully contribute to the improvement of the gut barrier function of obese and overweighed people.